Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (955)	12/29/1997 11:44:00 PM
From: Jim Baker	Read Replies (1) \| Respond to of 3702

Mo Winn -- "so the only source of funding to back a speculative intellectual property company such as Techniclone is more equity issue" Not quite. Yes, biotech companies can obtain cash by selling stock. They also obtain cash by selling debt (convertible into stock at higher than market prices). They also obtain cash by doing deals -- partnerships, technology licensing, and so on. This last option is what you have overlooked, which is surprising since management's most recent press release stated that these are the opportunities it is pursuing. It is the hope of investors in TCLN that management will be successful in its publicly stated efforts to find licensing and development partners for several of its technologies. It is our hope that the whole (TCLN stock) is currently worth less than the sum of the parts (its technologies, as licensed to big pharma partners). By selling off small pieces of some technologies, the company may bring in some cash and may change the way its stock is valued. You see, in many industries there are often discrepancies between public and private market valuations. Big pharmas do not pay low prices for stock, they pay big prices for slivers of technologies. We hope that is the case here. Or else the stock indeed may be worth less.

To: Maurice Winn who wrote (955)	12/30/1997 5:51:00 PM
From: EZLibra	Read Replies (2) \| Respond to of 3702

Maurice, yes it is the real oil and will at least be a part of the cure for cancer. Yes I've been hosed before and am back for more. The new management will add Wall Street credibility which is completely lacking now. Though I don't think it will affect the Lym-1/VTA licenses it will certainly enhance future financings. When Roy Vagelos retired from Merck and joined struggling Regeneron the company was offered the world on a platter and the stock went from $3 to $25. And their P III failed. You might want to read the home page, it's excellent;http://www.techniclone.com Are you in New Zealand now? from your profile, of course.